• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    11/12/24 9:03:38 AM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    SC 13G 1 ss4106433_sc13g.htm SCHEDULE 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    ESTABLISHMENT LABS HOLDINGS INC.

    (Name of Issuer)

     

    Common Shares, No Par Value

    (Title of Class of Securities)

     

    G31249108

    (CUSIP Number)

     

    November 7, 2024

    (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

     

     

     
     

     

    CUSIP NO. G31249108 SC 13G Page 2 of 8

     

    1

    NAMES OF REPORTING PERSONS

     

    Qatar Investment Authority

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Qatar

      5 SOLE VOTING POWER
    NUMBER OF   1,755,311
    SHARES 6 SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   0
    EACH 7 SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON   1,755,311
    WITH: 8 SHARED DISPOSITIVE POWER
        0
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,755,311 (See Item 4)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.03%(1)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

           

     

    (1) Calculated assuming 29,115,632 Common Shares (as defined below) outstanding following the offering of 765,696 Common Shares, both as described in the Issuer’s prospectus supplement filed with the Securities and Exchange Commission (“SEC”) under Rule 424(b)(5) on November 8, 2024, and after giving effect to the closing of that offering.

     

     

     
     
    CUSIP NO. G31249108 SC 13G Page 3 of 8

     

     

    Item 1(a).Name of Issuer:

    Establishment Labs Holdings Inc. (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    Building B15 and 25

    Coyol Free Zone

    Alajuela

    Costa Rica

     

    Item 2(a).Name of Person Filing:

    Qatar Investment Authority (the “Reporting Person”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

    Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61), Doha, State of Qatar.

     

    Item 2(c).Citizenship:

    Qatar.

     

    Item 2(d).Title of Class of Securities:

    Common Shares, No Par Value (the “Common Shares”).

     

    Item 2(e).CUSIP Number:

    G31249108.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    Amount beneficially owned:

    1,755,311

    Percent of class: 6.03%

     

    Number of shares as to which the person has:

     

    (i)       Sole power to vote or to direct the vote

    1,755,311

     

    (ii)       Shared power to vote or to direct the vote

    0

     

    (iii)       Sole power to dispose or to direct the disposition of

    1,755,311

     

    (iv)       Shared power to dispose or to direct the disposition of

    0

     

    The percentage in this Item 4 has been calculated assuming 29,115,632 Common Shares outstanding following the offering of 765,696 Common Shares as described in the Issuer’s prospectus supplement filed with the SEC under Rule 424(b)(5) on November 8, 2024 and gives effect to the closing of that offering.

     

     

     
     

     

    CUSIP NO. G31249108 SC 13G Page 4 of 8

     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    See Exhibit A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    Not Applicable.

     

     

     

     

     

     

     

     

     

     

     
     
    CUSIP NO. G31249108 SC 13G Page 5 of 8

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 12, 2024

     

     

    QATAR INVESTMENT AUTHORITY

     

      By:  /s/ Andrew Watkins
        Name: Andrew Watkins**
       

    Title: Associate General Counsel, Head of Compliance

           

     

     

    **Evidence of authority to sign on behalf of Qatar Investment Authority is set forth in a Certificate of Incumbency dated February 02, 2022, and included as Exhibit B hereto.

     

     

     

     

     

     

     

     

     

     

     

     

       

     

     

    CUSIP NO. G31249108 SC 13G Page 6 of 8

     

    INDEX TO EXHIBITS

     

    Exhibit No. Description

     

    AItem 7 Information
    BCertificate of Incumbency

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $ESTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    8/20/2025$60.00Buy
    Canaccord Genuity
    5/16/2025$62.00Buy
    BTIG Research
    5/14/2025$48.00Hold → Buy
    Needham
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    More analyst ratings

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

    Revenue for the quarter ended December 31, 2025 is expected to be between $64.0 million and $65.0 million, including between $17.0 million and $17.5 million from Motiva sales in the United States. Revenue for fiscal year 2025 is expected to be in the range of $210.5 million to $211.5 million, representing growth of approximately 27% over 2024, including between $45.4 million and $45.9 million from Motiva sales in the United States. The Company's year-end 2025 cash position is expected to be approximately $75.5 million, an increase of $4.8 million from the end of the third quarter of 2025. Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated

    1/12/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the events. About Establishment Labs Establishmen

    12/31/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted Motiva® implants for approval in primary and revision breast reconstruction to the U.S. Food and Drug Administration (FDA). The products were previously approved by the FDA for use in breast augmentation on September 27, 2024. "Expanding our FDA approval from breast augmentation to reconstruction is an important step forward for women's health," said Jeff Ehrhardt, Senior Vice President and Establishment Labs' General Manager of North America. "Breast reconstruction

    12/29/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Establishment Labs with a new price target

    Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00

    8/20/25 8:52:36 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    BTIG Research initiated coverage on Establishment Labs with a new price target

    BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00

    5/16/25 8:05:11 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs upgraded by Needham with a new price target

    Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00

    5/14/25 8:49:26 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewin Nicholas Sheridan bought $98,410 worth of shares (2,600 units at $37.85) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/14/25 10:58:27 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Lewin Nicholas Sheridan bought $78,880 worth of shares (2,300 units at $34.30) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/13/25 11:02:28 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: Chief Executive Officer Caldini Filippo bought $100,320 worth of shares (2,850 units at $35.20), increasing direct ownership by 9% to 35,245 units (SEC Form 4)

    4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/11/25 4:02:37 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    SEC Filings

    View All

    Establishment Labs Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    1/14/26 8:01:04 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    1/12/26 8:03:33 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Establishment Labs Holdings Inc.

    SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/14/25 4:44:05 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    View All

    Establishment Labs Publishes 15 Years of Motiva Data in 2025 Post-Market Surveillance Report

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc

    10/9/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Appoints Peter Caldini as Chief Executive Officer

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

    5/7/25 4:00:00 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Announces CEO Transition

    Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active

    1/13/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Financials

    Live finance-specific insights

    View All

    Establishment Labs Reports Third Quarter 2025 Financial Results

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2025. Third Quarter Highlights and Outlook (Unaudited) Third quarter worldwide revenue of $53.8 million, an increase of 33.8% from the year ago period. Revenue included $11.9 million of Motiva sales in the United States. 2025 revenue expected to exceed $210 million, an increase from previous guidance of $208 million to $212 million. Third quarter gross margin of 70.1% compared to 63.9% in the year-ago period and 68.8% in th

    11/5/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs to Announce Third Quarter 2025 Financial Results on November 5

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww

    10/22/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Reports Second Quarter 2025 Financial Results

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the United States. 2025 revenue guidance increased to $208 million to $212 million from $205 million to $210 million, year over year growth of 25%–28%, with at least $40 million in US Motiva revenue. Second quarter gross ma

    8/7/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chacon Quiros Juan Jose was granted 10,285 shares, increasing direct ownership by 5% to 224,433 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    1/9/26 4:41:03 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Schutter Edward J was granted 257 shares, increasing direct ownership by 0.19% to 138,272 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    1/5/26 5:20:10 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Slotkin Bryan was granted 222 shares, increasing direct ownership by 0.75% to 29,970 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    1/5/26 5:19:37 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 12:54:20 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 9:03:38 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

    SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    2/14/24 4:51:40 PM ET
    $ESTA
    Industrial Specialties
    Health Care